Progyny expects Q4 2025 revenue, net income, Adj. EBITDA slightly above prior guidance

Progyny, Inc.

2025-FY EPS reported $0.65 revenue$1,288,661,000

CEO cites favorable Q4 member engagement vs. November guidance.
Expects Q4 revenue, net income and Adjusted EBITDA slightly above prior ranges.
Update excludes non-cash impacts from departure of President Michael Sturmer.
Presenting at 44th Annual JP Morgan Healthcare Conference on Jan 13, 2026.
No specific revised figures provided; guidance remains qualitative.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.